Article first published online: 14 MAR 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 57, Issue 5, pages 1734–1741, May 2013
How to Cite
Tseng, Y.-T., Chang, S.-Y., Liu, W.-C., Sun, H.-Y., Wu, C.-H., Wu, P.-Y., Lu, C.-L., Hung, C.-C. and Chang, S.-C. (2013), Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus–infected and -uninfected men who have sex with men. Hepatology, 57: 1734–1741. doi: 10.1002/hep.26210
Potential conflict of interest: Nothing to report.
Supported by the Taiwan Centers for Disease Control (grants AIDS-97-1002 and EU099059).
Preliminary analyses of these data were presented as Abstract O-556 at the 21st European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom, March 31-April 3, 2012.
- Issue published online: 22 APR 2013
- Article first published online: 14 MAR 2013
- Accepted manuscript online: 19 DEC 2012 11:43AM EST
- Manuscript Accepted: 9 DEC 2012
- Manuscript Received: 7 JUN 2012
The purpose of this prospective cohort study was to compare the serologic response between human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) receiving two and three doses of hepatitis A virus (HAV) vaccine and HIV-uninfected MSM receiving two doses of HAV vaccine. Between June 2009 and December 2010, 582 MSM aged 18 to 40 years who were seronegative for HAV were enrolled in the study. HIV-infected MSM received either two doses of HAV vaccine (1,440 enzyme-linked immunosorbent assay units) (n = 140) with the second dose given at week 24 or three doses (n = 225) with the second and third dose given at weeks 4 and 24, respectively, while HIV-uninfected MSM (n = 217) received two doses. The primary endpoint was seroconversion at week 48. The geometric mean concentration (GMC) of anti-HAV antibody was determined at weeks 48 and 72. At week 48, the seroconversion rate was 75.7%, 77.8%, and 88.5% in intention-to-treat analysis for two-dose HIV-infected, three-dose HIV-infected, and two-dose HIV-uninfected MSM, respectively. The GMC of anti-HAV antibody at week 48 for three-dose HIV-infected MSM (2.29 ± 0.73 log10 mIU/mL) was significantly higher than that for two-dose HIV-infected MSM (1.94 ± 0.66; P < 0.01), but was lower than HIV-uninfected MSM (2.49 ± 0.42; P < 0.01). Multivariate analysis revealed higher CD4 counts (adjusted odds ratio [AOR] for per 50 cells/μL increase, 1.13; 95% confidence interval [CI], 1.05-1.21) and undetectable plasma HIV RNA load (AOR, 1.90; 95% CI, 1.10-3.28) before HAV vaccination were predictive of seroconversion in HIV-infected patients. Conclusion: Serologic response rate to three and two doses of HAV vaccine was similar in HIV-infected MSM, which was lower than that in HIV-uninfected MSM receiving two doses. HAV vaccination in HIV-infected patients with a higher CD4 count and suppression of HIV replication increased the seroconversion rate. (HEPATOLOGY 2013)